OPT 1.37% 37.0¢ opthea limited

Phase 3 Trials, page-48

  1. 3,246 Posts.
    lightbulb Created with Sketch. 98
    i been trying to figure out plausible explanations for SP weakness recently - had a light bulb moment today. SP decline correlates well with the increased US covid deaths staring early Nov.

    On face value - COVID seems to killing the target patient group for wet AMD ie. the elderly.

    By the end of pandemic, I expect around 500-600k deaths in the US alone with probably decent % (maybe 15-20%) of those may have wAMD. So that’s a reduction of the over total 1M wAMD US patients by 50-100k or 5-10% hence the market may be discounting lower revenues for all players.

 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.